Imad Al‐Dakkak

534 total citations
24 papers, 282 citations indexed

About

Imad Al‐Dakkak is a scholar working on Immunology, Nephrology and Hematology. According to data from OpenAlex, Imad Al‐Dakkak has authored 24 papers receiving a total of 282 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 8 papers in Nephrology and 8 papers in Hematology. Recurrent topics in Imad Al‐Dakkak's work include Complement system in diseases (14 papers), Renal Diseases and Glomerulopathies (8 papers) and Adenosine and Purinergic Signaling (4 papers). Imad Al‐Dakkak is often cited by papers focused on Complement system in diseases (14 papers), Renal Diseases and Glomerulopathies (8 papers) and Adenosine and Purinergic Signaling (4 papers). Imad Al‐Dakkak collaborates with scholars based in United States, United Kingdom and Canada. Imad Al‐Dakkak's co-authors include Eilish McCann, Eric M. Maiese, Girish Prajapati, Abhijit Gadkari, Seema Patel, Éric Rondeau, Benjamin L. Miller, Gianluigi Ardissino, Daniel Landau and Nicholas J.A. Webb and has published in prestigious journals such as Blood, Neurology and Journal of the American Society of Nephrology.

In The Last Decade

Imad Al‐Dakkak

21 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Imad Al‐Dakkak United States 8 112 107 76 39 36 24 282
Isabel Galán Spain 11 51 0.5× 79 0.7× 42 0.6× 56 1.4× 10 0.3× 33 303
Ramazan Danış Türkiye 13 39 0.3× 39 0.4× 40 0.5× 55 1.4× 30 0.8× 41 310
Benson J. Ouma United States 9 119 1.1× 59 0.6× 17 0.2× 67 1.7× 24 0.7× 14 317
Caroline Cromwell United States 8 47 0.4× 44 0.4× 26 0.3× 29 0.7× 80 2.2× 17 250
Anant Gokarn India 8 14 0.1× 78 0.7× 8 0.1× 59 1.5× 68 1.9× 60 281
Maria Marluce S. Vilela Brazil 8 66 0.6× 59 0.6× 6 0.1× 56 1.4× 10 0.3× 14 187
Ibrahim Wada United Kingdom 12 103 0.9× 38 0.4× 9 0.1× 71 1.8× 17 0.5× 25 726
Alex Kasembeli Kenya 7 10 0.1× 115 1.1× 189 2.5× 39 1.0× 5 0.1× 7 310
Enric Contreras Spain 9 65 0.6× 58 0.5× 31 0.4× 16 0.4× 151 4.2× 11 301
Rachel Hellemans Belgium 12 28 0.3× 53 0.5× 49 0.6× 78 2.0× 9 0.3× 37 390

Countries citing papers authored by Imad Al‐Dakkak

Since Specialization
Citations

This map shows the geographic impact of Imad Al‐Dakkak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Imad Al‐Dakkak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Imad Al‐Dakkak more than expected).

Fields of papers citing papers by Imad Al‐Dakkak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Imad Al‐Dakkak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Imad Al‐Dakkak. The network helps show where Imad Al‐Dakkak may publish in the future.

Co-authorship network of co-authors of Imad Al‐Dakkak

This figure shows the co-authorship network connecting the top 25 collaborators of Imad Al‐Dakkak. A scholar is included among the top collaborators of Imad Al‐Dakkak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Imad Al‐Dakkak. Imad Al‐Dakkak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schaefer, Franz, et al.. (2024). Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab. Kidney International Reports. 9(9). 2648–2656. 5 indexed citations
2.
Licht, Christoph, Imad Al‐Dakkak, Nicole M. Isbel, et al.. (2024). Characterization of patients with aHUS and associated triggers or clinical conditions: A Global aHUS Registry analysis. Nephrology. 29(8). 519–527. 5 indexed citations
3.
4.
Wang, Yan, Imad Al‐Dakkak, Katherine Garlo, et al.. (2023). Atypical Hemolytic Uremic Syndrome Treated With Ravulizumab or Eculizumab: A Claims-Based Evaluation of Health Care Resource Utilization and Clinical Outcomes in the United States. Kidney Medicine. 5(8). 100683–100683. 4 indexed citations
5.
Halimi, Jean‐Michel, Imad Al‐Dakkak, Gianluigi Ardissino, et al.. (2022). Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry. Journal of Nephrology. 36(3). 817–828. 13 indexed citations
6.
Al‐Dakkak, Imad, Gianluigi Ardissino, Laurence Greenbaum, et al.. (2022). FC 115: Long-Term Outcomes in Eculizumab-Treated Kidney Transplant Patients Enrolled in the Global Atypical Haemolytic Uraemic Syndrome Registry. Nephrology Dialysis Transplantation. 37(Supplement_3). 1 indexed citations
7.
8.
Fakhouri, Fádi, Marie Scully, Gianluigi Ardissino, et al.. (2021). Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. Journal of Nephrology. 34(5). 1581–1590. 30 indexed citations
9.
Rondeau, Éric, Gianluigi Ardissino, Imad Al‐Dakkak, et al.. (2021). Pregnancy in Women with Atypical Hemolytic Uremic Syndrome. ˜The œNephron journals/Nephron journals. 146(1). 1–10. 11 indexed citations
10.
Al‐Dakkak, Imad, et al.. (2021). Evaluating the Effectiveness of Apixaban Additional Risk Minimisation Measures Using Surveys in Europe. Pharmaceutical Medicine. 35(2). 123–135.
11.
Greenbaum, Larry A., Christoph Licht, Vasileios S. Nikolaou, et al.. (2020). Functional Assessment of Fatigue and Other Patient-Reported Outcomes in Patients Enrolled in the Global aHUS Registry. Kidney International Reports. 5(8). 1161–1171. 11 indexed citations
12.
Lapeyraque, Anne‐Laure, Martin Bitzan, Imad Al‐Dakkak, et al.. (2020). Clinical Characteristics and Outcome of Canadian Patients Diagnosed With Atypical Hemolytic Uremic Syndrome. Canadian Journal of Kidney Health and Disease. 7. 2247776397–2247776397. 4 indexed citations
13.
Rondeau, Éric, Spero R. Cataland, Imad Al‐Dakkak, et al.. (2019). Eculizumab Safety: Five-Year Experience From the Global Atypical Hemolytic Uremic Syndrome Registry. Kidney International Reports. 4(11). 1568–1576. 44 indexed citations
14.
Rondeau, Éric, Gianluigi Ardissino, Imad Al‐Dakkak, et al.. (2019). SP075PREGNANCY OUTCOMES IN PATIENTS ENROLLED IN THE GLOBAL aHUS REGISTRY. Nephrology Dialysis Transplantation. 34(Supplement_1). 1 indexed citations
15.
16.
Johnson, Peter, Wolfgang Greiner, Imad Al‐Dakkak, & Samuel Wagner. (2015). Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International. 2015. 1–9. 15 indexed citations
17.
Al‐Dakkak, Imad, et al.. (2014). A Systematic Review of Health State Utility Values for Advanced Ovarian Cancer. Value in Health. 17(7). A645–A645. 4 indexed citations
18.
19.
Maiese, Eric M., Imad Al‐Dakkak, Eilish McCann, et al.. (2012). PIN45 The Impact of HIV Treatment-Related Adverse Events on Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. Value in Health. 15(4). A245–A245. 2 indexed citations
20.
Al‐Dakkak, Imad, Seema Patel, Eilish McCann, et al.. (2012). The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis. AIDS Care. 25(4). 400–414. 110 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isabel Galán Breakdown of academic impact, for papers by Ramazan Danış Breakdown of academic impact, for papers by Benson J. Ouma Breakdown of academic impact, for papers by Caroline Cromwell Breakdown of academic impact, for papers by Anant Gokarn Breakdown of academic impact, for papers by Maria Marluce S. Vilela Breakdown of academic impact, for papers by Ibrahim Wada Breakdown of academic impact, for papers by Alex Kasembeli Breakdown of academic impact, for papers by Enric Contreras Breakdown of academic impact, for papers by Rachel Hellemans
Rankless by CCL
2026